Discover investment opportunities in List Of Psychedelic Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in List Of Psychedelic Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in List Of Psychedelic Stocks using our Smart AI Filter.
7 stocks found for "List Of Psychedelic Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.17 | ±100.0% | -4.1 | 0.00% | |||
0.49 | ±66.7% | -1.1 | 0.00% | |||
0.82 | ±100.0% | -13.0 | 0.00% | |||
0.56 | ±100.0% | -6.0 | 0.00% | |||
1.02 | ±100.0% | -0.3 | 0.00% | |||
1.28 | ±88.5% | -5.2 | 0.00% | |||
0.47 | ±100.0% | -0.9 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
The consensus price target hints at an 114.1% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read moreatai Life Sciences (ATAI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read moreThe consensus price target hints at an 831.4% upside potential for Cybin Inc. (CYBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read moreThe average of price targets set by Wall Street analysts indicates a potential upside of 107.3% in GH Research (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read moreQ: What drives the interest in psychedelic stocks like CMPS and ATAI?
A: Interest in psychedelic stocks is primarily driven by their potential in mental health treatment, particularly for disorders like depression and PTSD. Companies like CMPS (Compass Pathways) and ATAI Life Sciences are at the forefront of developing innovative therapies, which could transform traditional approaches to mental health.
Q: How do stocks like MNMD perform during economic downturns?
A: Psychedelic stocks, including MNMD, might exhibit higher volatility during economic downturns due to their speculative nature and reliance on clinical trial outcomes. Investors should consider the broader market environment and each company's financial resilience.
Q: Are psychedelic stocks like CYBN associated with high growth potential?
A: Many investors consider psychedelic stocks, such as CYBN, to have high growth potential due to the promising research in treating mental health disorders. Regulatory changes and successful clinical trials could substantially impact their growth trajectory.
Q: What are typical risks associated with investing in RLMD?
A: Investing in RLMD and similar psychedelic stocks entails risks like regulatory uncertainty, clinical trial dependencies, and potential competition from larger pharmaceutical firms. These stocks are also susceptible to market sentiment and emotional swings.
Q: Which factors should be considered for dividend-focused investors looking at GHRS?
A: Investors focusing on dividends might find psychedelic stocks like GHRS less appealing, as many companies in this sector prioritize research and development over dividend payouts. Checking each company's financial statements for dividend presence is recommended.
Q: How do SEEL's industry advancements affect its investment appeal?
A: SEEL’s advancements in psychedelic-assisted therapy could enhance its appeal as an investment, especially with growing societal acceptance and potential for new therapeutic breakthroughs. Its performance can be tied closely to R&D success and market adoption.